97 related articles for article (PubMed ID: 17309179)
1. Synergistic interaction between a mixed ligand copper (II) chelate complex and two anticancer agents in T47D human breast cancer cells in vitro.
Geromichalos GD; Trafalis DT; Katsoulos GA; Papageorgiou A; Dalezis P; Triandafillidis EB; Hadjikostas CC; Athanassiou A
J BUON; 2006; 11(4):469-76. PubMed ID: 17309179
[TBL] [Abstract][Full Text] [Related]
2. Synergistic interaction between a novel mixed ligand copper(II) chelate complex and a panel of anticancer agents in T47D human breast cancer cells in vitro.
Geromichalos GD; Katsoulos GA; Trafalis DT; Hadjikostas CC; Papageorgiou A
J BUON; 2005; 10(2):235-40. PubMed ID: 17343335
[TBL] [Abstract][Full Text] [Related]
3. Cytotoxic effects of a mixed ligand copper(II) chelate complex against a panel of human and murine cancer cells in vitro. Theoretical study of the mechanism of biologic action through molecular modelling.
Geromichalos GD; Katsoulos GA; Papageorgiou A; Trafalis DT; Hadjikostas CC; Voyatzi SH; Stravoravdi P
J BUON; 2004; 9(4):433-41. PubMed ID: 17415851
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of Fatty Acid Synthase (FASN) synergistically enhances the efficacy of 5-fluorouracil in breast carcinoma cells.
Vazquez-Martin A; Ropero S; Brunet J; Colomer R; Menendez JA
Oncol Rep; 2007 Oct; 18(4):973-80. PubMed ID: 17786362
[TBL] [Abstract][Full Text] [Related]
5. Sequence-dependent administration of 5-fluorouracil maintains methotrexate antineoplastic activity in human estrogen-negative breast cancer and protects against methotrexate cytotoxicity in human bone marrow.
Das JR; Fryar-Tita EB; Zhou Y; Green S; Southerland WM; Bowen D
Anticancer Res; 2007; 27(6B):3791-9. PubMed ID: 18225534
[TBL] [Abstract][Full Text] [Related]
6. Comparison between CoFactor and Leucovorin activity applied in combination with 5-fluorouracil against two human colon cancer cell lines.
Bjelogrlić SK; Srdić T; Radulović S
J BUON; 2007; 12(1):71-6. PubMed ID: 17436405
[TBL] [Abstract][Full Text] [Related]
7. Potentiation by squalene of the cytotoxicity of anticancer agents against cultured mammalian cells and murine tumor.
Nakagawa M; Yamaguchi T; Fukawa H; Ogata J; Komiyama S; Akiyama S; Kuwano M
Jpn J Cancer Res; 1985 Apr; 76(4):315-20. PubMed ID: 2408954
[TBL] [Abstract][Full Text] [Related]
8. An in vitro investigation of the induction of apoptosis and modulation of cell cycle events in human cancer cells by bisphenanthroline-coumarin-6,7-dioxacetatocopper(II) complex.
Thati B; Noble A; Creaven BS; Walsh M; Kavanagh K; Egan DA
Chem Biol Interact; 2007 Jun; 168(2):143-58. PubMed ID: 17512508
[TBL] [Abstract][Full Text] [Related]
9. Large-bite bis(phosphite) ligand containing mesocyclic thioether moieties: synthesis, reactivity, group 11 (Cu(I), Au(I)) metal complexes and anticancer activity studies on a human cervical cancer (HeLa) cell line.
Suresh D; Balakrishna MS; Rathinasamy K; Panda D; Mague JT
Dalton Trans; 2008 May; (17):2285-92. PubMed ID: 18414753
[TBL] [Abstract][Full Text] [Related]
10. Cytotoxic effect, differentiation, inhibition of growth and theoretical calculations of an N,N-donor ligands and its platinum(II), palladium(II) and copper(II) complexes.
Miernicka M; Szulawska A; Czyz M; Lorenz IP; Mayer P; Karwowski B; Budzisz E
J Inorg Biochem; 2008 Feb; 102(2):157-65. PubMed ID: 17868889
[TBL] [Abstract][Full Text] [Related]
11. In vitro combined effect of a new series of copper (II) complexes with cisplatin or epirubicin on human breast and cervical cancer cell lines.
Geromichalos GD; Katsoulos GA; Hadjikostas CC; Kortsaris AH; Kyriakidis DA
Drugs Exp Clin Res; 1998; 24(2):93-104. PubMed ID: 9675550
[TBL] [Abstract][Full Text] [Related]
12. Apoptotic cell death: a possible key event in mediating the in vitro anti-proliferative effect of a novel copper(II) complex, [Cu(4-Mecdoa)(phen)(2)] (phen=phenanthroline, 4-Mecdoa=4-methylcoumarin-6,7-dioxactetate), in human malignant cancer cells.
Thati B; Noble A; Creaven BS; Walsh M; Kavanagh K; Egan DA
Eur J Pharmacol; 2007 Aug; 569(1-2):16-28. PubMed ID: 17585902
[TBL] [Abstract][Full Text] [Related]
13. The protection against trimetrexate cytotoxicity in human bone marrow by sequence-dependent administration of raloxifene, 5-fluorouracil/trimetrexate.
Das JR; Fryar EB; Green S; Southerland WM; Bowen D
Anticancer Res; 2006; 26(6B):4279-86. PubMed ID: 17201145
[TBL] [Abstract][Full Text] [Related]
14. [Antitumor effects of specific cyclooxygenase inhibitors combined with chemotherapeutic agents on gastric cancer cells in vitro].
Zhu FS; Chen XM; Wang YJ; Zhang X; Feng JX
Zhonghua Zhong Liu Za Zhi; 2007 Mar; 29(3):186-8. PubMed ID: 17649633
[TBL] [Abstract][Full Text] [Related]
15. The immunocytokine scFv23/TNF targeting HER-2/neu induces synergistic cytotoxic effects with 5-fluorouracil in TNF-resistant pancreatic cancer cell lines.
Lyu MA; Kurzrock R; Rosenblum MG
Biochem Pharmacol; 2008 Feb; 75(4):836-46. PubMed ID: 18082672
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of anticancer effects of newly synthesized dihydropyridine derivatives in comparison to verapamil and doxorubicin on T47D parental and resistant cell lines in vitro.
Bazargan L; Fouladdel S; Shafiee A; Amini M; Ghaffari SM; Azizi E
Cell Biol Toxicol; 2008 Apr; 24(2):165-74. PubMed ID: 17805981
[TBL] [Abstract][Full Text] [Related]
17. Cytotoxicity of copper(II) complexes of N-salicylidene-L-glutamate: modulation by ascorbic acid.
Paulikova H; Kadlecikova E; Suchanova M; Valkova Z; Rauko P; Hudecova D; Valent A
Neoplasma; 2008; 55(4):338-44. PubMed ID: 18505346
[TBL] [Abstract][Full Text] [Related]
18. Choline kinase down-regulation increases the effect of 5-fluorouracil in breast cancer cells.
Mori N; Glunde K; Takagi T; Raman V; Bhujwalla ZM
Cancer Res; 2007 Dec; 67(23):11284-90. PubMed ID: 18056454
[TBL] [Abstract][Full Text] [Related]
19. Synergistic antitumour effect of raltitrexed and 5-fluorouracil plus folinic acid combination in human cancer cells.
Avallone A; Di Gennaro E; Bruzzese F; Laus G; Delrio P; Caraglia M; Pepe S; Comella P; Budillon A
Anticancer Drugs; 2007 Aug; 18(7):781-91. PubMed ID: 17581300
[TBL] [Abstract][Full Text] [Related]
20. Sequence-dependent administration of raloxifene and 5-fluorouracil/pemetrexed protects against pemetrexed cytotoxicity in human bone marrow.
Das JR; Fryar-Tita EB; Green S; Southerland WM; Bowen D
Anticancer Res; 2007; 27(2):825-33. PubMed ID: 17465208
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
